VRTX logo

Vertex Pharmaceuticals Incorporated

VRTX
Healthcare|Biotechnology|US
$547.09
+4.59 (+0.85%)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87

Financials

Financial Snapshot

Market Cap
$138.67B
Enterprise Value
$140.17B
Revenue (TTM)
$12.99B
Net Income (TTM)
$3.98B
Cash & Investments
$6.30B
Net Cash
-$175.1M
Free Cash Flow (TTM)
$3.20B
Operating CF (TTM)
$3.69B
Debt/Equity
0.31

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$1.43B$2.09B$3.17B$3.81B$6.66B$7.52B$10.78B$11.22B$6.12B$6.61B$6.30B
Operating Cash Flow
$236.1M$844.9M$1.27B$1.57B$3.25B$2.64B$4.13B$3.54B-$492.6M$3.63B$3.69B
Free Cash Flow
$179.5M$585.5M$1.17B$1.49B$2.99B$2.41B$3.93B$3.28B-$790.3M$3.19B$3.20B
Capital Expenditure
-$56.6M-$259.4M-$95.5M-$75.5M-$259.8M-$235.0M-$204.7M-$258.4M-$297.7M-$437.6M-$492.3M
Financing Cash Flow
$133.3M$68.4M-$71.2M$126.8M-$505.3M-$1.48B-$67.7M-$562.2M-$1.49B-$2.26B$3.25B

R&D Spending

R&D (TTM)
$4.25B
R&D Intensity
32.7%
R&D Growth vs Prior
+13.2%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$1.70B$2.49B$3.05B$4.16B$6.21B$7.57B$8.93B$9.87B$11.02B$12.07B$12.99B
R&D Expense
$1.05B$1.32B$1.42B$1.75B$1.83B$3.05B$2.66B$3.16B$3.63B$3.75B$4.25B
R&D % of Revenue
61.6%53.2%46.5%42.1%29.5%40.3%29.7%32.0%32.9%31.1%32.7%
SG&A
$432.8M$496.1M$557.6M$658.5M$770.5M$840.1M$944.7M$1.14B$1.46B$1.75B$2.41B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$1.70B$2.49B$3.05B$4.16B$6.21B$7.57B$8.93B$9.87B$11.02B$12.07B$12.99B
Cost of Revenue
$210.5M$275.1M$409.5M$547.8M$736.3M$904.2M$1.08B$1.26B$1.53B$1.81B$1.87B
Gross Profit
$1.49B$2.21B$2.64B$3.62B$5.47B$6.67B$7.85B$8.61B$9.49B$10.27B$11.11B
R&D
$1.05B$1.32B$1.42B$1.75B$1.83B$3.05B$2.66B$3.16B$3.63B$3.75B$4.25B
SG&A
$432.8M$496.1M$557.6M$658.5M$770.5M$840.1M$944.7M$1.14B$1.46B$1.75B$2.41B
Operating Income
$9.9M$123.2M$635.1M$1.20B$2.86B$2.78B$4.31B$3.83B-$232.9M$4.76B$4.40B
Interest Expense
$81.4M$69.3M$34.1M$58.5M$58.2M$61.5M$54.8M$44.1M$30.6M$13.3M$39.3M
Pretax Income
-$67.4M-$15.7M$600.2M$1.39B$3.12B$2.73B$4.23B$4.38B$248.5M$4.64B$4.76B
Net Income
-$112.1M$263.5M$2.10B$1.18B$2.71B$2.34B$3.32B$3.62B-$535.6M$3.95B$3.98B
EPS (Diluted)
-0.461.048.094.5110.299.0112.8213.89-2.0815.3215.54
EBITDA
$75.5M$103.3M$706.8M$1.56B$3.28B$2.92B$4.44B$4.61B$486.3M$4.87B$4.97B
Shares Out. (M)
244.69253.22259.19260.67263.40259.90259.10260.50257.90258.00255.20

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$1.18B$1.67B$2.65B$3.11B$5.99B$6.79B$10.50B$10.37B$4.57B$5.09B$4.98B
Short-Term Investments
$250.6M$423.3M$518.1M$699.0M$670.7M$729.9M$274.5M$849.2M$1.55B$1.52B$1.32B
Total Current Assets
$1.83B$2.65B$3.84B$4.82B$8.13B$9.56B$13.23B$14.14B$9.60B$11.20B$11.69B
Total Assets
$2.89B$3.55B$6.25B$8.32B$11.75B$13.43B$18.15B$22.73B$22.53B$26.14B$32.74B
Total Current Liabilities
$792.5M$807.3M$1.12B$1.33B$1.88B$2.14B$2.74B$3.55B$3.56B$3.86B$5.00B
Long-Term Debt
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$1.85B$3.50B
Total Liabilities
$1.56B$1.50B$1.81B$2.23B$3.06B$3.33B$4.24B$5.15B$6.12B$7.48B$11.83B
Stockholders' Equity
$1.16B$2.03B$4.44B$6.09B$8.69B$10.10B$13.91B$17.58B$16.41B$18.67B$20.91B
Retained Earnings
-$5.37B-$5.12B-$2.99B-$1.85B$858.7M$3.20B$6.52B$10.14B$9.61B$13.56B$16.34B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$236.1M$844.9M$1.27B$1.57B$3.25B$2.64B$4.13B$3.54B-$492.6M$3.63B$3.69B
Capital Expenditure
-$56.6M-$259.4M-$95.5M-$75.5M-$259.8M-$235.0M-$204.7M-$258.4M-$297.7M-$437.6M-$492.3M
Free Cash Flow
$179.5M$585.5M$1.17B$1.49B$2.99B$2.41B$3.93B$3.28B-$790.3M$3.19B$3.20B
Investing Cash Flow
$104.5M-$437.7M-$202.2M-$1.24B$99.4M-$340.9M-$321.1M-$3.14B-$3.77B-$945.4M-$6.87B
Financing Cash Flow
$133.3M$68.4M-$71.2M$126.8M-$505.3M-$1.48B-$67.7M-$562.2M-$1.49B-$2.26B$3.25B
Issuance of Stock
$68.2M$344.8M$289.3M$343.2M$264.9M$102.0M$186.3M$134.6M$114.6M$127.7M$151.6M
Repurchase of Stock
$0.00$0.00-$350.0M-$192.0M-$539.1M-$1.43B-$172.0M-$427.6M-$1.18B-$2.02B-$1.30B
Net Debt Issuance
-$6.9M-$284.7M-$12.5M-$29.1M-$29.0M-$18.7M-$85.5M-$44.9M-$33.6M-$5.4M$4.50B
Stock Based Comp.
$237.7M$290.7M$325.0M$360.5M$429.5M$441.4M$491.3M$581.2M$698.5M$685.9M$668.6M
Net Change in Cash
$469.2M$481.5M$990.7M$462.4M$2.87B$811.2M$3.71B-$139.7M-$5.80B$515.6M$40.8M

Dilution Tracker

Shares Outstanding
253M
5-Year Share Growth
-2.0%
Stock Issuance (TTM)
$151.6M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
244.69253.22259.19260.67263.40259.90259.10260.50257.90258.00255.20
Change vs Prior %
—3.5%2.4%0.6%1.0%-1.3%-0.3%0.5%-1.0%0.0%-1.1%
Stock Issuance
$68.2M$344.8M$289.3M$343.2M$264.9M$102.0M$186.3M$134.6M$114.6M$127.7M$151.6M
Stock Repurchase
$0.00$0.00-$350.0M-$192.0M-$539.1M-$1.43B-$172.0M-$427.6M-$1.18B-$2.02B-$1.30B
Stock Based Comp.
$237.7M$290.7M$325.0M$360.5M$429.5M$441.4M$491.3M$581.2M$698.5M$685.9M$668.6M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
87.6%88.9%86.6%86.8%88.1%88.1%87.9%87.2%86.1%85.0%85.6%
Operating Margin %
0.6%5.0%20.8%28.8%46.0%36.7%48.2%38.8%-2.1%39.4%33.9%
Net Margin %
-6.6%10.6%68.8%28.3%43.7%30.9%37.2%36.7%-4.9%32.7%30.6%
EBITDA Margin %
4.4%4.1%23.2%37.5%52.9%38.5%49.7%46.7%4.4%40.3%38.2%
FCF Margin %
10.5%23.5%38.5%35.9%48.2%31.8%44.0%33.2%-7.2%26.5%24.7%
ROE %
-9.7%13.0%47.3%19.3%31.2%23.2%23.9%20.6%-3.3%21.2%20.1%
ROA %
-3.9%7.4%33.6%14.1%23.1%17.4%18.3%15.9%-2.4%15.1%12.1%
ROIC %
0.4%-26.1%12.4%14.4%25.1%21.0%21.8%16.4%2.6%18.1%12.8%
R&D / Revenue %
61.6%53.2%46.5%42.1%29.5%40.3%29.7%32.0%32.9%31.1%32.7%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
64.9%46.2%22.5%36.6%49.1%22.1%17.9%10.5%11.7%9.6%
Gross Profit
64.5%48.4%19.2%37.0%51.3%22.0%17.7%9.6%10.3%8.2%
Operating Income
102.1%1140.4%415.4%88.5%138.5%-2.6%54.8%-11.0%-106.1%2144.1%
Net Income
79.9%335.1%695.8%-43.9%130.4%-13.6%41.8%9.0%-114.8%838.1%
EPS (Diluted)
80.1%326.1%677.9%-44.3%128.2%-12.4%42.3%8.3%-115.0%836.5%
Operating Cash Flow
164.6%257.9%50.3%23.5%107.3%-18.7%56.2%-14.3%-113.9%837.2%
Free Cash Flow
143.7%226.1%100.6%27.2%100.4%-19.5%63.0%-16.5%-124.1%504.1%
R&D Expense
5.2%26.4%6.9%23.9%4.3%66.8%-13.0%19.1%14.8%3.4%
SG&A Expense
14.8%14.6%12.4%18.1%17.0%9.0%12.5%20.3%28.8%19.7%
Total Assets
15.9%22.5%76.1%33.2%41.3%14.3%35.1%25.2%-0.9%16.0%
Book Value / Share
20.9%49.7%112.5%35.9%41.0%17.2%38.6%25.6%-6.6%14.6%
Debt
1.8%-27.9%-3.2%12.8%40.8%3.8%-7.0%-10.1%116.4%121.9%
Diluted Shares
1.4%3.5%2.4%0.6%1.0%-1.3%-0.3%0.5%-1.0%0.0%

Valuation

P/E (TTM)34.94
10Y Low / Med / High20.09 / 28.96 / 141.38
P/S10.68
10Y Low / Med / High7.47 / 10.54 / 14.99
P/B6.63
10Y Low / Med / High5.32 / 7.07 / 18.38
EV/EBITDA28.22
10Y Low / Med / High14.51 / 34.46 / 350.92
EV/Revenue10.79
10Y Low / Med / High6.70 / 9.66 / 14.56
P/FCF43.30
10Y Low / Med / High18.84 / 35.87 / 99.95

Intrinsic Value Models (per share)

DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
-160.15141.3820.0947.8122.6424.1622.2728.96-193.6129.3234.94
P/S Ratio
10.5414.9913.8313.509.907.478.2810.629.419.6010.68
P/B Ratio
15.5218.389.509.247.075.605.325.966.326.216.63
EV/EBITDA
233.25350.9256.7034.4617.1617.4014.5120.69207.4323.5728.22
EV/Revenue
10.3414.5613.1512.929.086.707.219.669.159.5010.79

Analyst Estimates & Quality

Altman Z-Score
8.86
Safe
Piotroski F-Score
4
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$13.25B$14.68B$16.52B
Net Income$4.62B$5.07B$6.11B
EPS$18.23$20.16$24.09
# Analysts (EPS)151711

Revenue Segments

By Product

Segment202020212022202320242025
KALYDECO$802.9M$684.2M$553.2M$475.5M——
ORKAMBI$907.5M$771.6M$510.7M$326.0M——
SYMDEKO/SYMKEVI$628.6M$420.4M$180.0M$123.0M——
TRIKAFTA/KAFTRIO$3.86B$5.70B$7.69B$8.94B$10.24B$10.31B
Manufactured Product, Other————$781.5M$820.1M
ALYFTREK—————$837.8M

By Geography

Segment202020212022202320242025
Europe$1.13B$1.97B$2.71B$3.11B$3.45B$3.46B
UNITED STATES$4.83B$5.29B$5.70B$6.04B$6.68B$7.55B
Other, Non U.S.$249.9M$313.2M$525.9M$719.8M$881.3M—
Non-US—————$5.45B